Beeline Medicines’ BMS-licensed drug shows benefit in Phase II lupus trial
Beeline’s afimetoran is now set to advance to Phase III trials in SLE and is in a Phase II/III trial in CLE.
The post Beeline Medicines’ BMS-licensed drug shows benefit in Phase II lupus trial appeared first on Clinical Trials Arena .